Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. These findings highlight the current lack of robust clinical evidence supporting CBD as an effective treatment for fibromyalgia pain. Patients and clinicians should weigh this evidence carefully before selecting CBD as a primary pain management strategy.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomised controlled trial provides the first rigorous evidence directly comparing CBD efficacy to placebo in fibromyalgia patients, addressing a significant evidence gap given widespread off-label use of CBD for this condition. The findings establish a clinical benchmark for CBD’s analgesic efficacy in fibromyalgia that can inform evidence-based prescribing decisions and help differentiate placebo effects from true therapeutic benefit. These results will guide treatment algorithms for fibromyalgia management, potentially repositioning CBD within standard care protocols or identifying specific patient populations most likely to benefit.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This single-centre Danish trial provides valuable placebo-controlled evidence for CBD in fibromyalgia, a condition where patients often seek cannabis-based therapies due to limited conventional options, though the single-site design and relatively small sample size limit generalizability to diverse populations. The double-blind, randomized structure strengthens confidence compared to observational reports, but important confounders such as concurrent medications, baseline pain severity heterogeneity, and the high placebo response rate typical in fibromyalgia trials warrant careful interpretation. Additionally, CBD’s mechanism in fibromyalgia remains incompletely understood, and optimal dosing and patient selection criteria are not yet clearly defined. Clinically, this work supports discussing CBD as a potential adjunctive option for fibromyalgia patients who have exhausted or cannot tolerate conventional therapies, while emphasizing that it should complement rather than replace multimodal approaches including exercise, sleep hygiene, and psychological support.